ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

Paclitaxel [‘Taxol’] plus a platinum compound emerged as a contender for first-line treatment of ovarian cancer in a study presented during the 34th Annual Meeting of the American Society of Clinical Oncology (ASCO) [Los Angeles, US; May 1998]. Indeed, the evidence is now so convincing that leading UK ovarian cancer specialists drew up guidelines suggesting that all women with advanced ovarian cancer should have access to paclitaxel. Currently, not all UK health authorities fund this drug. Meanwhile, other studies presented during the meeting highlighted the role of adverse effects as cost drivers in cancer care.

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

Rapid development of endothelin (ET)-receptor antagonists by the pharmaceutical industry reflects the potential therapeutic significance of these agents. The primary therapeutic indication for ET-receptor antagonists has been congestive heart failure, and recent clinical data support a role for these novel agents in the treatment of this indication.*However, development of potent and selective endothelin antagonists has helped in the identification of other diseases in which this peptide may also play an important role. Pulmonary hypertension and perhaps asthma are leading contenders in the list of diseases likely to benefit from clinically effective, orally active ET-receptor antagonists, delegates were told at the International Conference of the American Lung Association and the American Thoracic Society [Chicago, US; April 1998].

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS